This is the first time that HAS is issuing a favorable opinion for the reimbursement of a technology...
Read moreThis updated bill contains some similar measures to those proposed in March as well as some addition...
Read moreAccording to the TLV, “The prices of medicines that have been on the market between 5 and 15 years...
Read moreUnder ODAP, a protocol is drawn up “with criteria for starting, stopping and effect of a medicine....
Read moreAn affordable and sustainable market access landscape is key to ensure patient access to life-saving...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreBased on a recent decision by the Interministerial Commission on Medicines Prices offering a price l...
Read moreThe National Recovery and Resilience Plan had extended the membership to the CPR and CTS until 28th...
Read moreReimbursed spending by the CNAM on out-patient care (including care from general practitioners [GPs]...
Read moreThe Italian Medicines Agency (AIFA) has announced that Roche’s Evyrsdi (risdiplam) is reimbursed w...
Read more